In this study (i) the host genome to identify susceptibility regions of infection, inflammation, and host defense, (ii) host response to Severe Acute Respiratory Syndrome-Corona-Virus-2 (SARS-CoV-2) infection, and (iii) viral sequence composition to define viral sequences which may be correlated with disease severity in addition to the metagenome of the throat swab will be analysed .
This study aims to recruit adult persons with diagnostically confirmed Corona-Virus-
Disease-19 (COVID-19) infection and with different disease manifestation who are included
into diagnostic or therapeutic care at the University Hospital Tübingen (UKT).
The COVID-19 Next-Generation-Sequencing (NGS) study aims to cover as many patients in Germany
as possible. It is expected to include in Phase 1 (pilot study): 250 patients with different
disease manifestation (extreme phenotypes) and individual risk factors by whole genome
analysis Phase 2 (verification study): 1.000 clinically well-defined patients to ensure a
broader range of overlapping phenotypes, to verify data from the pilot study.
Phase 3 (confirmation study): > 10.000 patients to increase the power (anticipated).
Genetic: Whole Genome Analysis
Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
Genetic: T-cell receptor (TCR) repertoire
Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
Genetic: SARS-CoV-2 viral composition
Determined by Next Generation sequencing
Inclusion Criteria:
- COVID-19 infection confirmed
- COVID-19 disease manifestation
- Age > 18 years
Exclusion Criteria:
- Missing informed consent of the patient/ legal guardian/ relatives
University Hospital Tübingen
Tübingen, Germany
Investigator: Olaf Rieß, Prof. Dr.
Contact: +49 7071 29
olaf.riess@med.uni-tuebingen.de
Olaf Rieß, Prof. Dr.
+49 (0)7071-29- - 72288
olaf.riess@med.uni-tuebingen.de
Michael Bitzer, Prof. Dr.
+49 (0)7071-29- - 80583
m.bitzer@med.uni-tuebingen.de
Olaf Rieß, Prof. Dr., Study Director
University Hospital Tübingen